Drugs & medicalClass II

MYLAN PHARMACEUTICALS INC recalls Amnesteem (Isotretinoin) Capsules, USP 40 mg, packaged in 3 x 10-Count Prescription Packs, Rx Only, Manufactured for: Mylan…

Failed Dissolution Specifications

Read the official notice →
Date
2026-03-11
Country
United States
Brand
Mylan Pharmaceuticals
Product
Amnesteem (Isotretinoin) Capsules, USP 40 mg, packaged in 3 x 10-Count Prescription Packs, Rx Only, Manufactured for: Mylan…
Classification
Class II
Units
Nationwide within the United States
Category
Drugs & medical
Source
FDA · Drug

Copied automatically from the US Food and Drug Administration. Details may be shortened or out of date; the official notice is the authoritative source. Disclaimer

What to do

  1. Check the product name, strength and lot number against the official notice.
  2. Do not stop a prescribed medicine without talking to your doctor or pharmacist first.
  3. Ask the pharmacy or supplier about a replacement or refund.

General guidance from Recall Atlas. The official notice from the US Food and Drug Administration has the exact models, batch codes and remedy, and it takes priority.

More Mylan Pharmaceuticals recalls

  1. 2026-09-09
  2. US
  3. 2026-08-26
  4. US
  5. 2026-08-05
  6. US
  7. 2025-03-26
  8. US
    Drugs & medicalClass II

    MYLAN PHARMACEUTICALS INC recalls Prasugrel Tablets, USP, 5 mg, 30-count bottle, Rx only, Manufactured for: Mylan Pharmaceuticals Inc., Morgantown, WV 26505 U.S.A., NDC…

    Failed Dissolution Specifications - low dissolution results

    FDA · DrugMYLAN PHARMACEUTICALS INCUS Nationwide.Official notice →
  9. 2022-08-03
  10. US
    Drugs & medicalClass I

    Mylan Pharmaceuticals Inc recalls Insulin Glargine (Insulin glargine-yfgn) Injection, 100 units/mL (U-100), 3 mL prefilled pens (NDC 49502-394-71), packaged in cartons…

    Labeling: Missing label: Label missing from some prefilled pens.

    FDA · DrugMylan Pharmaceuticals IncProduct was distributed nationwide within the United StatesOfficial notice →
  11. 2022-05-04
  12. US
All 12 Mylan Pharmaceuticals recalls →

Other drugs & medical recalls in the United States

  1. 2026-03-11
  2. US
    Drugs & medicalClass II

    Roche Diagnostics Operations, Inc. recalls cobas pro integrated solutions with cobas c 503 analytical units: cobas pro sample supply unit, material number 08464502001…

    Software defect, which allows the system to accept erroneous, non-monotonous calibrations for Spline-type assays. Cobas pro integrated solutions is an automated analyzer, intended for running qualitative,…

    FDA · DeviceRoche Diagnostics Operations, Inc.US Nationwide distribution.Official notice →
  3. US
    Drugs & medicalClass II

    GE Healthcare recalls GE Healthcare Centricity Universal Viewer Zero Footprint Client, Model Numbers: 2110344-039, 2110344-046, 2110344-047; System, Image…

    Under certain workflows, patient information shown in the viewer may not match the images displayed on Centricity Universal Viewer Zero Footprint Client (ZFP) with versions ZFP v6.0: SP11.6, SP11.6.0.1 and SP11.6.1 on…

    FDA · DeviceGE HealthcareWorldwide distribution - US Nationwide and the countries of Belarus, Brazil,…Official notice →
  4. US
    Drugs & medicalClass I

    Abiomed, Inc. recalls Impella RP Flex with SmartAssist. Product Code: 1000323.

    Differential pressure (dP) sensor in Impella RP devices may malfunction, causing sensor values to drift.

    FDA · DeviceAbiomed, Inc.Worldwide distribution - US Nationwide and the countries of Austria, Canada,…Official notice →
  5. US
    Drugs & medicalClass I

    StuffbyNainax recalls MR. 7 SUPER 700000 capsules, 1 capsule blister card, Distributed by mR. 7

    Marketed Without an Approved NDA/ANDA: FDA analysis revealed the presence of undeclared sildenafil and tadalafil

    FDA · DrugStuffbyNainaxProduct was distributed to 4 customers in the US.Official notice →
  6. US
    Drugs & medicalClass I

    Mohamed Hagar recalls Mojo Max Fusion XXX, 500 mg, one capsule per blister card, 20 count box, Distributed by: Max Nutrition Inc. UPC 6 78945 36675 0

    Marketed Without an Approved NDA/ANDA-FDA analysis revealed undeclared sildenafil (13.1 mg/capsule) and tadalafil (13.8 mg/capsule).

    FDA · DrugMohamed HagarU.S. NationwideOfficial notice →
  7. US
See all drugs & medical recalls →